Directorate Change

In brief · summary, not quotable

Chief Executive and Finance Director step down following shareholder feedback; Board reduced to two Non-executive Directors.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your CLBX notes

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that, following feedback and discussions with a significant shareholder, Andrew Newland, Chief Executive, and Ian Griffiths, Finance Director, have agreed to step down from their positions on the Board.

They remain committed and supportive of the Company and intend to support the Company with an orderly handover.

The Board now comprises Dr. Jan Groen, Non-executive Chairman, and Dr. Joseph Eid, Non-executive Director. It is proposed that the Board be expanded in due course.

For Research Use Only. Not for use in diagnostic procedures.

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.